New obesity drug candidate enters first human tests

NCT ID NCT07152002

Recruiting now Symptom relief Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study is testing an experimental drug called LY4064912 in 144 healthy volunteers and people with overweight or obesity. The main goal is to check safety and how the body handles the drug, not yet to prove it works for weight loss. Participants will receive either the drug or a placebo by injection or IV infusion, and researchers will monitor side effects and measure drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY4064912 (an experimental drug given as an injection under the skin or into a vein)
What this could lead to: If successful, this could lead to a new weight-loss treatment option for people with overweight or obesity.
What could go wrong: This is a very early Phase 1 trial focused on safety, not weight loss. The drug may cause side effects or fail to work in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY OVERWEIGHT OR OBESITY

Contacts and locations

Locations

Collaborative Neuroscience Network - CNS
RECRUITING

Los Alamitos, California, 90720, United States
ICON Early Phase Services
RECRUITING

San Antonio, Texas, 78209, United States
Lilly Centre for Clinical Pharmacology
RECRUITING

Singapore, 138623, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.